Celgene pricing convinces NICE to OK Vidaza

Celgene has struck a NICE deal. After an initial rebuff, the U.S.-based drugmaker's blood cancer drug Vidaza won a recommendation from the the National Institute for Health and Clinical Excellence to treat two types of leukemia and myelodysplastic syndromes. And it scored the win after offering the U.K. cost-effectiveness watchdog a cost-sharing arrangement it couldn't refuse.

The details of the new pricing scheme aren't public. But as InPharm reports, the price change brought Vidaza's cost per quality-adjusted life year--a measure NICE uses to evaluate price and effectiveness of drugs--to £47,000 from £63,000, or to roughly $76,000 from more than $101,000.

"[Vidaza] is not a cure, but it does have the potential to extend patients' lives by an average of nine months," NICE director Carole Longson said. "It is a very expensive drug, but the manufacturers have submitted a patient access scheme where the cost will be reduced."

NICE has developed a reputation for holding a tough line on costly drugs, particularly expensive cancer meds. To persuade the agency to accept their products for use by the National Health Service, drugmakers have been taking a variety of approaches to share the costs and risks of treatment. Johnson & Johnson negotiated the first breakthrough risk-sharing deal with its cancer drug Velcade, agreeing to refund the cost for treating patients who don't fully respond.

- see the release from NICE
- read the InPharm news

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.